Skip to main content

Immunovant, Inc.

IMVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001764013

In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.

13F holders, Q3 2025

Institutional positions in Immunovant, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
186
+19 vs. Q2 2025
Shares held
95.2M
−358.9K (−0.4%) vs. Q2 2025
Total value
$1.53B
+$5.65M (+0.4%) vs. Q2 2025
New holders
34
66 more added
Sold out
15
50 more reduced

2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q2 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting IMVT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2025: 186 institutions
Q1 2021: 120 institutionsQ2 2021: 110 institutionsQ3 2021: 119 institutionsQ4 2021: 118 institutionsQ1 2022: 112 institutionsQ2 2022: 94 institutionsQ3 2022: 112 institutionsQ4 2022: 133 institutionsQ1 2023: 142 institutionsQ2 2023: 147 institutionsQ3 2023: 181 institutionsQ4 2023: 228 institutionsQ1 2024: 209 institutionsQ2 2024: 197 institutionsQ3 2024: 182 institutionsQ4 2024: 187 institutionsQ1 2025: 194 institutionsQ2 2025: 169 institutionsQ3 2025: 186 institutionsQ4 2025: 197 institutionsQ1 2026: 216 institutionsQ2 2026: 226 institutions
Value heldQ3 2025: $1.53B
Q1 2021: $654.3MQ2 2021: $407.5MQ3 2021: $293.6MQ4 2021: $322.4MQ1 2022: $218.6MQ2 2022: $156.5MQ3 2022: $238.1MQ4 2022: $1.00BQ1 2023: $903.7MQ2 2023: $1.05BQ3 2023: $2.57BQ4 2023: $2.88BQ1 2024: $2.27BQ2 2024: $1.97BQ3 2024: $2.26BQ4 2024: $1.98BQ1 2025: $1.62BQ2 2025: $1.54BQ3 2025: $1.53BQ4 2025: $2.76BQ1 2026: $2.75BQ2 2026: $4.25B
Institutions holding IMVT and their total value by quarter
QuarterHoldersValue
Q2 2026226$4.25B
Q1 2026216$2.75B
Q4 2025197$2.76B
Q3 2025186$1.53B
Q2 2025169$1.54B
Q1 2025194$1.62B
Q4 2024187$1.98B
Q3 2024182$2.26B
Q2 2024197$1.97B
Q1 2024209$2.27B
Q4 2023228$2.88B
Q3 2023181$2.57B
Q2 2023147$1.05B
Q1 2023142$903.7M
Q4 2022133$1.00B
Q3 2022112$238.1M
Q2 202294$156.5M
Q1 2022112$218.6M
Q4 2021118$322.4M
Q3 2021119$293.6M
Q2 2021110$407.5M
Q1 2021120$654.3M

Institutions, Q3 2025

Shares, value and share of portfolio for each institution holding Immunovant, Inc.; share changes are against Q2 2025.

Institutions holding IMVT in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Twin Peaks Wealth Advisors, LLC0$00.00%−3−100.0%Sold out
Norges Bank––––Not filed
E Fund Management Co., Ltd.––––Not filed